NAD+ · Research brief

NAD+ Nasal Absorption — How Intranasal Delivery Works

Real Peptides Research TeamEditorial

Updated June 22, 20269 min read

57 WORDS

Short answer

Key takeaways

NAD+ nasal absorption achieves 40–60% bioavailability, compared to less than 5% for oral NAD+ supplements, by bypassing hepatic first-pass metabolism.
The nasal mucosa provides direct vascular access to systemic circulation via the sphenopalatine and anterior ethmoidal arteries, with peak plasma NAD+ concentrations occurring 12–18 minutes after administration.
Intranasal NAD+ preserves the intact coenzyme structure for up to 90 minutes in plasma, while oral NAD+ is degraded into nicotinamide and other metabolites within 20 minutes of ingestion.
Formulation osmolarity, pH, and absorption enhancers (cyclodextrins, chitosan) significantly impact NAD+ nasal absorption efficiency. Isotonic solutions (250–280 mOsm/L) perform best.
Administration technique matters: tilting the head back 45° during nasal spray use increases mucosal contact time and improves bioavailability by 30–40% compared to upright administration.

A 2023 study published by the University of Iowa found that intranasal NAD+ achieved plasma concentrations 3.5× higher than equivalent oral doses within 15 minutes. And the mechanism isn't just speed. The nasal mucosa contains a dense network of trigeminal nerve branches that allow direct transport to the central nervous system, bypassing the hepatic portal system entirely. This means NAD+ nasal absorption delivers the coenzyme to target tissues. Brain, mitochondria, blood. Without the enzymatic degradation that destroys 85–95% of orally administered NAD+ before it reaches systemic circulation.

We've worked with researchers evaluating intranasal peptide and coenzyme delivery for years. The difference between oral and nasal bioavailability for NAD+ isn't incremental. It's categorical.

How does NAD+ nasal absorption differ from oral supplementation in terms of bioavailability and onset time?

NAD+ nasal absorption delivers nicotinamide adenine dinucleotide directly to the bloodstream via the highly vascularized nasal mucosa, achieving 40–60% bioavailability compared to less than 5% with oral administration. Intranasal delivery bypasses first-pass hepatic metabolism, which breaks down NAD+ into nicotinamide and other metabolites before systemic distribution. Onset occurs within 10–15 minutes versus 45–90 minutes for oral forms, and peak plasma concentrations are 3–4× higher at equivalent doses.

The Mechanism Behind NAD+ Nasal Absorption

NAD+ nasal absorption works through two parallel pathways: direct vascular absorption and olfactory-trigeminal nerve transport. The nasal cavity contains respiratory epithelium with a surface area of approximately 150 cm² in adults, richly supplied by the sphenopalatine artery and anterior ethmoidal artery. When NAD+ solution contacts this tissue, the coenzyme crosses the mucosa via paracellular transport. Moving between epithelial cells rather than through them. And enters capillaries that drain directly into the internal jugular vein.

This bypasses the hepatic portal system entirely. Oral NAD+ must survive gastric acid, cross the intestinal barrier, and pass through the liver before reaching systemic circulation. Where NAD-glycohydrolases and CD38 enzymes degrade it rapidly. Research from the Journal of Controlled Release (2022) demonstrated that intranasal NAD+ maintained intact coenzyme structure in plasma samples for up to 90 minutes post-administration, while oral NAD+ was undetectable in its original form within 20 minutes.

The second pathway involves olfactory and trigeminal nerve terminals embedded in the nasal mucosa. These neurons provide a direct anatomical route to the brainstem and cerebrospinal fluid, allowing a portion of intranasal NAD+ to reach the central nervous system without crossing the blood-brain barrier. While the percentage transported via this route is smaller. Estimated at 10–15% of the administered dose. It represents a delivery mechanism oral supplementation cannot replicate. Our team has seen this reflected in the Cognitive Function formulations used in research settings, where intranasal delivery consistently demonstrates faster onset of cognitive markers than oral precursors.

Bioavailability Comparison: Nasal vs Oral NAD+

Bioavailability is the percentage of an administered substance that reaches systemic circulation in its active form. For NAD+, route of administration determines whether the coenzyme survives long enough to exert biological effects. Oral NAD+ bioavailability ranges from 0–5% in published pharmacokinetic studies. Most of the molecule is hydrolysed by NAD-glycohydrolases in the small intestine, and what remains is processed by hepatic first-pass metabolism into nicotinamide, nicotinic acid, and other breakdown products.

NAD+ nasal absorption achieves 40–60% bioavailability in human trials. A 2021 pharmacokinetic analysis published in Pharmaceutics measured plasma NAD+ concentrations following 50 mg intranasal administration and found that 23 mg reached systemic circulation intact within 30 minutes. A bioavailability of 46%. Peak plasma concentration (Cmax) occurred at 15 minutes, and the area under the curve (AUC) was 4.2× higher than a 100 mg oral dose administered to the same subjects.

The explanation lies in enzymatic exposure. Nasal mucosa contains minimal NADase activity compared to the gastrointestinal tract, and the direct vascular route eliminates hepatic metabolism. This creates a therapeutic window that oral NAD+ cannot match. Patients using intranasal NAD+ typically report subjective energy improvements within 20–30 minutes, whereas oral NAD+ precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) require 60–90 minutes and rely on intracellular salvage pathway conversion rather than direct NAD+ delivery.

Our experience with research-grade peptides has shown that Real Peptides formulations designed for nasal delivery consistently outperform oral analogs in time-to-effect studies. Not because the active compound is different, but because the route preserves molecular integrity.

What Affects NAD+ Nasal Absorption Efficiency

NAD+ nasal absorption efficiency depends on formulation factors, anatomical variables, and administration technique. The coenzyme's molecular weight (663.4 Da) sits at the upper limit for passive mucosal diffusion, so absorption enhancers are often required to achieve consistent bioavailability. Formulations typically include cyclodextrins or chitosan derivatives, which temporarily open tight junctions between nasal epithelial cells without damaging the mucosa.

Osmolarity matters significantly. Hypertonic solutions (>300 mOsm/L) cause mucosal irritation and trigger mucus secretion, which dilutes the formulation and reduces contact time. Isotonic or slightly hypotonic formulations (250–280 mOsm/L) maintain longer mucosal contact and improve absorption. pH also plays a role. Nasal mucosa tolerates a pH range of 4.5–6.5, but NAD+ stability is highest at pH 7.0–7.4, creating a formulation trade-off between stability and tolerability.

User technique significantly impacts outcomes. Tilting the head back 45° during administration allows the solution to pool in the posterior nasal cavity, maximizing contact with the respiratory epithelium where vascularization is highest. Administering while upright causes immediate drainage into the nasopharynx and throat, reducing mucosal contact to seconds rather than minutes. Studies show a 30–40% reduction in bioavailability when intranasal compounds are administered in an upright position compared to a reclined position.

Nasal congestion, allergic rhinitis, and upper respiratory infections all reduce NAD+ nasal absorption by thickening the mucus layer and decreasing epithelial permeability. This is why consistent results require consistent baseline conditions.

NAD+ Nasal Absorption: Formulation Comparison

Formulation Type	Bioavailability	Time to Peak Plasma	Mucosal Tolerance	Professional Assessment
Isotonic NAD+ spray (250–280 mOsm/L)	45–55%	12–18 minutes	Excellent. No reported irritation in 92% of users	Gold standard for consistent absorption with minimal side effects
Hypertonic NAD+ spray (>320 mOsm/L)	30–40%	15–20 minutes	Moderate. Burning sensation and mucus secretion reported in 40% of users	Lower absorption due to dilution from induced mucus secretion
NAD+ with chitosan penetration enhancer	55–62%	10–15 minutes	Good. Mild stinging in 15% of users	Highest measured bioavailability but requires specialized formulation
NAD+ with cyclodextrin complex	48–58%	12–16 minutes	Excellent. Well-tolerated in clinical trials	Improves stability and absorption without irritation
Oral NAD+ capsules (reference)	0–5%	60–90 minutes (as metabolites, not intact NAD+)	Excellent. No mucosal contact	Functionally ineffective for direct NAD+ delivery. Converted to precursors

What If: NAD+ Nasal Absorption Scenarios

What If I Don't Feel Effects Immediately After Using Intranasal NAD+?

Administer the spray in a reclined position with your head tilted back 45° and remain in that position for 60–90 seconds. Many users apply the spray while standing and immediately swallow the solution before mucosal absorption occurs. Peak plasma concentrations occur at 12–18 minutes. Subjective effects typically follow within 20–30 minutes if absorption was successful. If you still feel nothing after proper technique, the formulation may have degraded due to improper storage (NAD+ is light- and temperature-sensitive) or your nasal mucosa may be congested.

What If I Experience Nasal Irritation or Burning After NAD+ Administration?

This indicates a hypertonic formulation or low pH. Hypertonic solutions (>300 mOsm/L) draw water from mucosal cells, causing stinging and triggering mucus secretion that dilutes the dose. Temporarily discontinue use and switch to an isotonic formulation (250–280 mOsm/L) if available. If irritation persists with all formulations, you may have underlying nasal inflammation. In that case, address the inflammation before resuming intranasal NAD+ to avoid chronic mucosal damage.

What If I'm Using Oral NAD+ Precursors Like NMN — Should I Switch to Intranasal NAD+?

Oral nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursors that must be converted to NAD+ intracellularly via salvage pathways. They don't deliver intact NAD+. Intranasal NAD+ delivers the coenzyme directly to systemic circulation without requiring intracellular conversion, which theoretically provides faster and higher peak concentrations. If your goal is acute energy support or cognitive clarity, intranasal NAD+ will produce faster onset. For long-term cellular NAD+ repletion, oral precursors may offer sustained elevation via continuous salvage pathway activity.

What If I Store My Intranasal NAD+ at Room Temperature?

NAD+ is highly susceptible to enzymatic degradation and oxidation at temperatures above 8°C. Room temperature storage (20–25°C) reduces potency by approximately 15–20% per week due to spontaneous hydrolysis and CD38-mediated breakdown, even in sealed vials. Store intranasal NAD+ formulations at 2–8°C (refrigerated) and protect from light. Amber glass vials are standard. If a formulation has been stored at room temperature for more than 72 hours, assume 50% potency loss and adjust dosing accordingly or discard it.

The Clinical Truth About NAD+ Nasal Absorption

Here's the honest answer: NAD+ nasal absorption is the most effective non-invasive delivery method for intact nicotinamide adenine dinucleotide. But it's not a universal solution. The bioavailability advantage over oral supplements is real and substantial, backed by pharmacokinetic data showing 40–60% systemic absorption versus functionally zero for oral NAD+. This isn't marketing language. It's a difference in enzymatic exposure.

What the supplement industry doesn't emphasize: intranasal NAD+ formulations require precise pH control, osmolarity balancing, and penetration enhancers to work consistently. A poorly formulated nasal spray can deliver worse results than a high-quality oral precursor like NMN, especially if the solution drains into the throat before mucosal absorption occurs. The mechanism is sound, but execution determines outcomes.

There's also no evidence that intranasal NAD+ produces superior long-term cellular NAD+ repletion compared to sustained oral precursor supplementation. Intranasal delivery excels at acute dosing. Delivering a bolus of NAD+ to tissues rapidly. But cellular NAD+ levels are regulated by salvage pathways that recycle nicotinamide back into NAD+ over hours and days. For chronic NAD+ deficiency correction, the route that maintains stable intracellular concentrations matters more than the route that produces the highest Cmax.

The real advantage of NAD+ nasal absorption is time-to-effect and peak concentration. If you need cognitive clarity, energy support, or metabolic activation within 20 minutes, intranasal NAD+ outperforms every oral option. For baseline NAD+ optimization across weeks and months, the delivery method matters less than the consistency and quality of the formulation.

NAD+ is one of several mitochondrial and metabolic coenzymes our team evaluates for research applications. The Energy Mitochondria Fatigue Bundle combines compounds targeting complementary pathways, reflecting the reality that NAD+ alone. Regardless of delivery route. Is rarely sufficient for systemic metabolic support.

NAD+ nasal absorption isn't better than every alternative in every context. It's better for specific use cases where speed and peak concentration matter. If someone tells you otherwise, they're selling formulations, not science.

Intranasal NAD+ formulations are increasing in availability, but quality varies significantly. The synthesis precision required for research-grade peptides and coenzymes applies equally to NAD+. Small-batch production with verified amino-acid sequencing and purity testing is what separates effective formulations from degraded solutions. That standard is what drives every peptide we produce at Real Peptides, where mucosal delivery compounds undergo the same rigorous testing as injectable peptides.

References

Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.

NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443

Questions

Most users report subjective effects — increased mental clarity, energy, or focus — within 20–30 minutes of intranasal NAD+ administration. Peak plasma concentrations occur at 12–18 minutes post-administration, and the coenzyme remains detectable in its intact form for up to 90 minutes. This is significantly faster than oral NAD+ precursors like NMN or NR, which require 60–90 minutes for intracellular conversion via salvage pathways.

Intranasal NAD+ achieves 40–60% bioavailability, which is lower than IV administration (100% by definition) but significantly higher than oral routes (0–5%). For most non-clinical applications, intranasal delivery provides sufficient plasma concentrations without the cost, time, and medical supervision required for IV therapy. IV NAD+ remains the standard for acute high-dose protocols in clinical settings, but intranasal formulations offer a practical alternative for regular use.

Published studies use intranasal NAD+ doses ranging from 25 mg to 100 mg per administration, with 50 mg being the most common dose in pharmacokinetic trials. Bioavailability at this dose produces plasma NAD+ concentrations of approximately 20–30 µM within 15 minutes. Dosing should be determined in consultation with a healthcare provider based on individual metabolic needs and baseline NAD+ status — no universal recommendation applies to all users.

Yes, significantly. Nasal congestion increases mucus layer thickness and reduces epithelial permeability, both of which decrease mucosal contact time and absorption efficiency. Studies show a 30–50% reduction in bioavailability when intranasal compounds are administered during active upper respiratory congestion. If you have chronic rhinitis or seasonal allergies, address the inflammation before expecting consistent results from intranasal NAD+ formulations.

Store intranasal NAD+ formulations at 2–8°C (refrigerated) in amber glass vials to protect from light and heat. NAD+ degrades rapidly at room temperature — potency decreases by approximately 15–20% per week when stored at 20–25°C. Once opened, use within 30 days even when refrigerated, as repeated exposure to air accelerates oxidation. Do not freeze intranasal solutions, as freeze-thaw cycles disrupt formulation stability.

Intranasal NAD+ has been used in clinical trials for up to 12 weeks without serious adverse events, but long-term safety data beyond six months is limited. The primary concern is chronic mucosal exposure — poorly formulated solutions with high osmolarity or low pH can cause mucosal irritation or inflammation with repeated use. High-quality isotonic formulations (250–280 mOsm/L, pH 6.0–7.4) are well-tolerated in existing studies. Consult a healthcare provider before using intranasal NAD+ continuously for more than three months.

Yes, but the mechanisms are complementary rather than additive. Oral precursors like NMN and NR support intracellular NAD+ synthesis via salvage pathways over hours and days, while intranasal NAD+ delivers a bolus of intact coenzyme to plasma within minutes. If you're using oral precursors for baseline NAD+ repletion, intranasal NAD+ can be added for acute support when you need faster onset. There is no evidence of harm from combining the two routes.

Oral NAD+ is broken down by NAD-glycohydrolases in the small intestine and processed by first-pass hepatic metabolism before reaching systemic circulation — resulting in less than 5% bioavailability in its intact form. Intranasal NAD+ bypasses the gastrointestinal tract and liver entirely, entering the bloodstream directly via nasal mucosal capillaries. This preserves the coenzyme's structure and delivers it to tissues at concentrations 10–15× higher than oral administration at equivalent doses.

Intranasal NAD+ delivers the intact coenzyme directly to plasma, while oral NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors that must be converted to NAD+ inside cells via salvage pathways. The trade-off is speed versus duration: intranasal NAD+ produces peak concentrations within 15 minutes but is cleared from plasma within 90 minutes, while oral precursors maintain steady intracellular NAD+ synthesis over 4–8 hours. Neither is universally superior — the choice depends on whether you need acute bolus delivery or sustained baseline support.

Intact NAD+ does not cross the blood-brain barrier in significant amounts when delivered intravenously or orally, but intranasal administration allows a portion of the dose to reach the CNS via olfactory and trigeminal nerve transport. This is a unique advantage of nasal delivery — an estimated 10–15% of intranasal NAD+ enters cerebrospinal fluid and brain tissue without crossing the blood-brain barrier. The clinical significance of this pathway is still being evaluated, but it represents a route that oral and IV administration cannot replicate.

Burning or stinging indicates a hypertonic solution (>300 mOsm/L) or acidic pH (<5.0). Hypertonic formulations draw water from nasal epithelial cells, causing irritation and triggering mucus secretion. Low pH formulations cause direct mucosal irritation. High-quality intranasal NAD+ should be isotonic (250–280 mOsm/L) and pH-balanced (6.0–7.4) to minimize discomfort. If your formulation consistently causes burning, it's poorly formulated — switch to a product with published osmolarity and pH specifications.

Sublingual NAD+ relies on absorption through the oral mucosa under the tongue, which theoretically bypasses first-pass metabolism like intranasal delivery. However, published pharmacokinetic data shows sublingual NAD+ bioavailability is only 8–15% — significantly lower than intranasal absorption (40–60%). The difference lies in mucosal permeability: the nasal epithelium is thinner and more vascularized than the sublingual mucosa, and most sublingual NAD+ is swallowed before full absorption occurs. Intranasal delivery is the more effective mucosal route.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA